{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-000246","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2025-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.260551+00:00","generated_at":"2026-05-28T16:29:22.574630+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eterna Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025","bullets":["Notice received December 30, 2024: closing bid price below $1 for 30 consecutive business days.","Company has until June 30, 2025 to regain compliance for 10 consecutive business days.","If not cured, may request a second 180-day period if other listing standards are met.","Stock continues to trade on Nasdaq under symbol ERNA with no immediate delisting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-000246","json":"https://secwatch.observer/filing/0001493152-25-000246.json","markdown":"https://secwatch.observer/filing/0001493152-25-000246.md","text":"https://secwatch.observer/filing/0001493152-25-000246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T16:29:22.574630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b116a62cc6636c9575e90d98e5b965b5438a5a7a","claim":"Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063806","ticker":"ILLR","company_name":"Triller Group Inc.","filed_at":"2026-06-02T12:26:59+00:00","headline":"Triller gets Nasdaq bid-price exception until June 30, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063806","json":"https://secwatch.observer/filing/0001213900-26-063806.json","markdown":"https://secwatch.observer/filing/0001213900-26-063806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/ea0292925-8k_triller.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"May 29, 2026, the Nasdaq Hearings Panel (the\n“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant\nTriller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,\n2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following\na successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which\nmodified a previous December 26, 2025 decision by a Nasdaq Hearings Panel","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001493152-26-026520","ticker":"NUTR","company_name":"NUSATRIP Inc","filed_at":"2026-06-01T11:10:27+00:00","headline":"NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026520","json":"https://secwatch.observer/filing/0001493152-26-026520.json","markdown":"https://secwatch.observer/filing/0001493152-26-026520.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)\nfrom the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s\nnon-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely\nfile its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended\nMarch 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm"}},{"accession":"0001213900-26-063141","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-06-01T11:05:20+00:00","headline":"Twenty One Capital receives NYSE non-compliance notice; audit committee lacks independence; cure due June 5","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063141","json":"https://secwatch.observer/filing/0001213900-26-063141.json","markdown":"https://secwatch.observer/filing/0001213900-26-063141.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/0001213900-26-063141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/ea0292652-8ka1_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"cator\nand website references will be removed when the Company regains compliance with all NYSE quantitative and corporate governance listing\nstandards. The Company expects to appoint, as soon as practicable, an additional member to the audit committee who meets the independence\nrequirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the Listed Company Manual. Forward-Looking Statements Certain statements in this periodic report are “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words indi","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/0001213900-26-063141-index.htm"}},{"accession":"0001213900-26-063100","ticker":"COLA","company_name":"Columbus Acquisition Corp/Cayman Islands","filed_at":"2026-05-30T01:56:47+00:00","headline":"Columbus Acquisition regains compliance with Nasdaq $50M MVLS rule; delisting risk removed","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063100","json":"https://secwatch.observer/filing/0001213900-26-063100.json","markdown":"https://secwatch.observer/filing/0001213900-26-063100.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/0001213900-26-063100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/ea0292674-8k_columbus.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"May 28, 2026, the Company the Company received a written notice from Nasdaq notifying the Company that the Staff has determined that\nfor the last 10 consecutive business days, from May 13, 2026 to May 27, 2026, the Company’s MVLS has been $50 million or greater.\nAccordingly, the Company has regained compliance with the MVLS Rule and the Staff has indicated that the matter is now closed. 1 SIGNATURES Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized. Columbus\n Acq","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/0001213900-26-063100-index.htm"}},{"accession":"0001683168-26-004399","ticker":"CSAI","company_name":"CLOUDASTRUCTURE, INC.","filed_at":"2026-05-29T21:09:11+00:00","headline":"Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004399","json":"https://secwatch.observer/filing/0001683168-26-004399.json","markdown":"https://secwatch.observer/filing/0001683168-26-004399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/cloud_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"May 26, 2026, Cloudastructure,\nInc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq\nStock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for\nthe period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional\ntime to review and confirm the accounting treatment for its outstand","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm"}},{"accession":"0001493152-26-026412","ticker":"CETY","company_name":"Clean Energy Technologies, Inc.","filed_at":"2026-05-29T20:57:27+00:00","headline":"Clean Energy Technologies receives Nasdaq delisting notice for late Q1 filing","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026412","json":"https://secwatch.observer/filing/0001493152-26-026412.json","markdown":"https://secwatch.observer/filing/0001493152-26-026412.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1329606/000149315226026412/0001493152-26-026412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1329606/000149315226026412/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"May 26, 2026, Clean Energy Technologies, Inc. (the “ Company ”) received a written notice (the “ Notice ”)\nfrom the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not\nin compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”) because the Company had not yet filed its Quarterly\nReport on Form 10-Q for the period ended March 31, 2026 (the “ Quarterly Report ”). The\nRule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The Notice has\nno immediate effect on the listing","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1329606/000149315226026412/0001493152-26-026412-index.htm"}},{"accession":"0001193805-26-000723","ticker":"GURE","company_name":"GULF RESOURCES, INC.","filed_at":"2026-05-29T20:45:30+00:00","headline":"Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000723","json":"https://secwatch.observer/filing/0001193805-26-000723.json","markdown":"https://secwatch.observer/filing/0001193805-26-000723.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/e665526_8k-gulfresources.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing\nQualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000149315225000246/0001493152-25-000246-index.htm","comparable_excerpt":"May 26, 2026, Gulf Resources\n(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq\nStock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for\nthe quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form\n10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq\nListing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}